nor-Cannabichromene | 2552823-92-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: nor-Cannabichromene
• 英文别名: 7-butyl-5-hydroxy-2-methyl-2-(4-methylpent-3-enyl)chromene-6-carboxylic acid
• CAS: 2552823-92-2
• 化学式: C₂₁H₂₈O₄
• 分子量: 344.451
• InChiKey: LBLHSYKUFLXTQM-UHFFFAOYSA-N

反应信息

• 作为产物：
  描述：

  在 caesium carbonate 、 苯硫酚 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以48 %的产率得到nor-Cannabichromene
  参考文献：
  名称：

  次要大麻素作为皮肤炎症抑制剂：化学合成和生物学评价

  摘要：

  尽管治疗性植物的使用已有数千年的历史，但对大麻多样化生物医学潜力的有意开发直到最近才引起人们的关注。生物活性研究主要集中在大麻二酚（CBD）和四氢大麻酚（THC）上，有关更广泛的大麻组“次要植物大麻素”的信息有限。在此背景下，我们的研究目标是合成含有 3 或 4 个碳原子侧链的次要大麻素，重点是大麻醇 (CBG) 和大麻色烯 (CBC) 类似物。利用已知的创新策略，我们合成了 11 种 C3 和 C4 类似物，其中 5 种是皮肤炎症抑制剂，其中 CBG-C4 酯衍生物成为最有效的化合物。

  DOI：

  10.1021/acs.jnatprod.4c00212

文献信息

• BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS
  申请人：Ginkgo Bioworks, Inc.

  公开号：US20220195472A1

  公开（公告）日：2022-06-23

  Aspects of the disclosure relate to biosynthesis of cannabinoids and cannabinoid precursors in recombinant cells and in vitro.
• [EN] STABLE FORMULATIONS OF DRONABINOL<br/>[FR] FORMULATIONS STABLES DE DRONABINOL
  申请人：TRYAGX LABS INC

  公开号：WO2021163023A1

  公开（公告）日：2021-08-19

  Described herein are formulations, methods of manufacturing, and methods of treatment using formulations of cannabinoids that are stable at room temperature for at least about one to two years. In one embodiment, the composition is an oxidatively stable formulation of dronabinol.
• [EN] METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES<br/>[FR] MÉTHODES POUR L'IDENTIFICATION, LA STRATIFICATION ET LE TRAITEMENT DE MALADIES DU SYSTÈME NERVEUX CENTRAL
  申请人：[en]DUKE UNIVERSITY

  公开号：WO2022081350A2

  公开（公告）日：2022-04-21

  Described herein are methods for identifying mitochondrial defects using metabolomics and genetic analyses and using this information to stratify patients and to correct for metabolic defects in a precision medicine approach. One embodiment is a method for isolating and analyzing samples containing one or more mitochondrial biomarker metabolites or genetic markers useful for the analysis, identification, stratification or classification, and treatment of metabolic changes associated with a CNS or neuropsychiatric disease in a subject and therapies useful for the treatment thereof. In one aspect, the biomarker metabolites comprise mitochondrial metabolites including acylcarnitines and endocannabinoids and the genetic analyses focus on metabolic enzymes or transport mechanisms.
• [EN] PRODUCTION OF CANNABINOIDS/PHYTOCANNABINOIDS WITH A PLANT EXTRACT<br/>[FR] PRODUCTION DE CANNABINOÏDES/PHYTOCANNABINOÏDES À L'AIDE D'UN EXTRAIT VÉGÉTAL
  申请人：[en]TECHNISCHE UNIVERSITÄT DARMSTADT

  公开号：WO2022101306A1

  公开（公告）日：2022-05-19

  The present invention relates to a process for the production of a compound of Formula (I), wherein the process comprises the step of reacting a plant extract having prenyltransferase activity with a compound of Formula (II) and geranyl pyrophosphate (GPP) having Formula (III) to produce the compound of Formula (I), wherein the plant extract is not a plant extract obtainable from a plant that naturally produces cannabinoids/phytocannabinoids. Accordingly, the present invention relates to a process for the production of a compound of Formula (I), wherein the process comprises the step of reacting a plant extract having prenyltransferase activity with a compound of Formula (II) and geranyl pyrophosphate (GPP) having Formula (III) to produce the compound of Formula (I), wherein the plant extract is not Cannabis sativa plant extract. Further, the present invention relates to the process for the production of a compound of Formula (IV), wherein the process comprises producing a compound of Formula (I) by the process as described herein and converting the compound of Formula (I) to the compound of Formula (IV) in the presence of the tetrahydrocannabinolic acid synthase (THCAS; EC 1.21.3.7). The present invention also relates to a process for the production of a compound of Formula (V) wherein the process comprises producing a compound of Formula (I) by the process as described herein and converting the compound of Formula (I) to a compound of Formula (V) in the presence of the THCAS (EC 1.21.3.7), cannabidiolic acid synthase (CBDAS; EC 1.21.3.8) and/or cannabichromenic acid synthase (CBCAS; EC 1.3.3.-). Further, the present invention relates to a process for the production of a compound of Formula (VI) wherein the process comprises producing a compound of Formula (I) by the process as described herein and converting the compound of Formula (I) to a compound of Formula (VI) in the presence of the CBDAS (EC 1.21.3.8).